It is a multi-kinase inhibitor belonging to a unique class of orally administered small molecule therapeutics targeting multiple protein kinases, including kinases involved in tumour angiogenesis (VEGFR1, -2, -3, TIE2), oncogenesis (KIT, RET, RAF-1, BRAF, BRAFV600E), and the tumour microenvironment (PDGFR, FGFR) [6]. Here, PDGFRB is linked to neoplasm.